2014

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Northwest Biotherapeutics, Inc. (NWBO) To Contact The Firm

NEW YORK, July 4, 2014 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Northwest Biotherapeutics, Inc. ("Northwest" or the "Company") (NASDAQ: NWBO).

On June 19, 2014, TheStreet.com published an article stating that "[t]he prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct… MD Anderson is running the DCVax-Direct phase I/II clinical trial with funding from Northwest Bio[therapeutics], which makes the hospital's criticism of the company's tactics even more significant."

Following this news, the price of Northwest shares declined by $1.79 per share, or over 19%, to close on June 19, 2014 at $7.18 per share.

Request more information now by clicking here: www.faruqilaw.com/NWBO.  There is no cost or obligation to you.

Take Action

If you invested in Northwest stock or options prior to June 19, 2014 and would like to discuss your legal rights, visit www.faruqilaw.com/NWBO.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Northwest's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation.  The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation.  The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

Logo - http://photos.prnewswire.com/prnh/20120119/MM38856LOGO

SOURCE Faruqi & Faruqi, LLP



RELATED LINKS
http://www.faruqilaw.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.